Fresenius Medical Care Announces Receipt of Subpoena

Bad Homburg, Germany -- April 6, 2005 — Fresenius Medical Care AG ("the Company") (Frankfurt Stock Exchange: FME, FME3) (NYSE: FMS, FMS-p), the world's largest provider of dialysis products and services, today announced that its wholly-owned subsidiary, Fresenius Medical Care Holdings, Inc., received on April 1, 2005 a subpoena from the U.S. Department of Justice, Eastern District of Missouri in St. Louis. The subpoena requires production of a broad range of documents relating to the Company's operations, including documents related to, among other things, clinical quality programs, business development activities, medical director compensation and physician relations, joint ventures and our anemia management program. The subpoena covers the period from December 1, 1996 through the present.

The subpoena was issued in connection with a joint civil and criminal investigation of allegations against the Company. The Company intends to cooperate with the government's investigation. To the knowledge of the Company, the government has not initiated legal proceedings against the Company at this time, and it is not possible to predict whether proceedings might be initiated or when the investigation may be concluded. Counsel for the Company had an initial conversation with the United States Attorney's Office, Eastern District of Missouri, on Tuesday April 5, 2005 to begin discussions related to this investigation. The Company intends to meet with representatives of the government to review the government's priorities and the production of responsive documents.

Ben Lipps, Chief Executive Officer of Fresenius Medical Care, commented: "We understand and respect that the government has the right and responsibility to investigate allegations or concerns. We have commented many times before on our pride in our global team's commitment to quality and compliance. In light of our system of internal controls and the procedures we follow under our corporate compliance program and the Corporate Integrity Agreement, I am confident of our position on these issues and other regulatory compliance matters. We look forward to reviewing these extensive compliance processes which we have adopted."